HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Transcatheter closure of perimembranous ventricular septal defect using Amplatzer ductal occluder.

AbstractOBJECTIVE:
To show that transcatheter closure of perimembranous ventricular septal defect (PMVSD) with the Amplatzer ductal occluder (ADO, AGA Medical Corp, Plymouth, Minnesota) is a safe and effective treatment option.
BACKGROUND:
Transcatheter closure of PMVSD is a challenging procedure. Recently, the Amplatzer PMVSD occluder (APMVSDO, AGA Medical Corp, Plymouth, Minnesota) has been shown to be effective in closing hemodynamically significant PMVSDs. However, the high incidence of complete atrioventricular block (CAVB) after device occlusion of a PMVSD has been a hot issue as well.
METHODS:
Among several devices used in closing PMVSD percutaneously, we prefer the ADO because of the anatomic resemblance between PMVSD with aneurysm and patent ductus arteriosus, and it has no right ventricular disc which may contribute to the occurrence of CAVB.
RESULTS:
Between August 2009 and May 2012, 21 patients (5 males and 16 females) underwent percutaneous PMVSD closure using ADO. The patients' ages ranged from 3 to 42 years (median: 7 years), and their weights ranged from 18 kg to 60 kg (median: 27 kg). All patients showed echocardiographic signs of left ventricular volume overload and trivial to small mitral regurgitation (Qp/Qs = 1.7 ± 0.4). The mean defect size of the right ventricular side was 4.3 ± 1.0 mm. Devices 2 mm larger than the measured narrowest VSD diameter were selected in most patients. The ADOs were successfully implanted in all patients without any significant complications except one transient CAVB, one case of delivery wire fracture, and one case of surgery due to significant residual leak. Small residual shunts were observed immediately after the device implantation, but they disappeared during follow-up for 18 of 20 patients. The mean follow-up period was 20 ± 9 months, and CAVB or aortic regurgitation was not observed in all patients.
CONCLUSION:
Transcatheter closure of PMVSD with the ADO is a safe and promising treatment option, but long-term follow-up in a large number of patients would be warranted.
AuthorsSang Mi Lee, Jin Young Song, Jae Young Choi, Sang Yoon Lee, Jae Sook Paik, So Ick Chang, Woo Seop Shim, Seong Ho Kim
JournalCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (Catheter Cardiovasc Interv) Vol. 82 Issue 7 Pg. 1141-6 (Dec 01 2013) ISSN: 1522-726X [Electronic] United States
PMID23554093 (Publication Type: Journal Article)
CopyrightCopyright © 2013 Wiley Periodicals, Inc.
Topics
  • Adolescent
  • Adult
  • Atrioventricular Block (etiology)
  • Cardiac Catheterization (adverse effects, instrumentation)
  • Child
  • Child, Preschool
  • Female
  • Heart Septal Defects, Ventricular (diagnosis, physiopathology, therapy)
  • Hemodynamics
  • Humans
  • Male
  • Prosthesis Design
  • Septal Occluder Device
  • Time Factors
  • Treatment Outcome
  • Ventricular Function

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: